Trial Profile

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GI 102 (Primary) ; GI 102 (Primary) ; Bevacizumab; Doxorubicin; Eribulin; Paclitaxel; Pembrolizumab; Trastuzumab-deruxtecan
Indications Gastric cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms KEYNOTE-G08
Sponsors GI Innovation

25 Nov 2024 Planned End Date changed from 30 Jun 2025 to 24 Apr 2027.
25 Nov 2024 Planned primary completion date changed from 30 Apr 2025 to 12 Nov 2025.
25 Nov 2024 Planned number of patients changed from 92 to 358.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com